BASKING RIDGE, N.J., Aug. 6 /EMWNews/ -- Millennium

Biotechnologies, Inc., a wholly owned subsidiary of Millennium

Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) today named Mark C.

Mirken its new Chief Executive Officer and Chairman of its Board of

Directors.



    Mirken has been President and Chief Operating Officer of Millennium

since he joined the Company in September of 2007. Mirken will replace Jerry

Swon who has been Chief Executive Officer and Board Chairman since 2001.

Mr. Swon will be retiring from these positions to pursue other business

interests.



    "In the short time that Mark has been with Millennium he has

demonstrated a complete set of business skills and decisive leadership in

designing, developing, marketing and selling a Ready-to-Drink product that

is gaining significant market acceptance. Mark has created a new and

dynamic product and a growing domestic and international customer base. The

Agreements he has developed with Ferring Pharmaceuticals of Canada, a

division of the international billion dollar drug conglomerate, is the

beginning of significant international opportunities. Our three year

manufacturing contract with General Electric subsidiary Farmland Dairies

will anchor the domestic growth of our Ready-to-Drink product in the

immuno-compromised and Long Term Care and Sports Channels. At this point in

the Company's history we are extremely fortunate to have a person with

Mark's business development capabilities and strategic vision to continue

to build and develop the Company's products and line extensions in both its

clinical and sports businesses," said Mr. Swon.



    "I am extremely excited about the ability to move Millennium in the

commercialization of its product lines and leverage and enhance its

intellectual assets. I feel strongly that we must shed our past and move

quickly to establish beachheads in the lucrative channels we have initiated

while concurrently developing similar opportunities in related platforms.

This development and execution of our targeted nutritional supplements,

both powdered and Ready-to-Drink will lead the transformation of Millennium

from a small start-up company with a promising technology to a global

enterprise with increasing value to our shareholders," stated Mirken.



    Prior to joining Millennium, Mark was consultant to numerous Wall

Street funds across a broad category of disciplines. He was also the Chief

Operating Officer of Turbochef Technologies, Inc. When he left in 2004, the

market cap had increased from under twenty million dollars to approximately

half a billion dollars. Mirken holds an A.B. from the University of North

Carolina and a J.D. from the University of North Carolina School of Law at

Chapel Hill.

    About Millennium



    Millennium's six marketed products form its advanced line of

nutritional formulas. Resurgex Select(R) is a whole foods-based,

calorically dense, high-protein nutritional formula developed for cancer

patients undergoing chemotherapy or radiation treatments. Resurgex(R) and

Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in

antioxidants that provide nutritional support post-treatment. Millennium

also created Surgex(TM) sports nutrition formula to address the nutritional

concerns of professional, Olympic, and amateur elite athletes. These

athletes often experience similar symptoms post-workout to those battling

immuno-compromised conditions, such as fatigue, loss of lean muscle,

oxidative stress, and reduced immune function. Resurgex Essential(TM) and

Resurgex Essential Plus(TM) are comprehensive, calorically dense formulas

that meet and succeed the nutritional requirements of the assisted living

community.



    Statements in this news release regarding future financial and

operating results, future growth in R&D programs, potential applications of

the Millennium's technology, opportunities for the Millennium, and any

other statements about the future expectations, beliefs, goals, plans, or

prospects expressed constitute forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. Any

statements that are not statements of historical fact (including statements

containing the words 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,'

'estimates,' and similar expressions) should also be considered to be

forward-looking statements. There are a number of important factors that

could cause actual results or events to differ materially from those

indicated by such forward- looking statements including: limited operating

history, need for future capital, risks inherent in the development and

commercialization of potential products, protection of Millennium's

intellectual property, and economic conditions generally. Additional

information on potential factors that could affect results and other risks

and uncertainties are detailed from time to time in Millennium's periodic

reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with

the Securities and Exchange Commission ('SEC'). Millennium Biotechnologies,

Inc.